Efficacy and safety of rifampicin for multiple system atrophy: a randomised, double-blind, placebo-controlled trial.

@article{Low2014EfficacyAS,
  title={Efficacy and safety of rifampicin for multiple system atrophy: a randomised, double-blind, placebo-controlled trial.},
  author={Phillip A. Low and David P. Robertson and Sid Gilman and Horacio Kaufmann and Wolfgang Singer and Italo Biaggioni and Roy L Freeman and Susan L. Perlman and Robert A. Hauser and William P Cheshire and Stephanie L Lessig and Steven Vernino and Jay N. Mandrekar and William D. Dupont and Thomas C. Chelimsky and Wendy R. Galpern},
  journal={The Lancet. Neurology},
  year={2014},
  volume={13 3},
  pages={268-75}
}
BACKGROUND No available treatments slow or halt progression of multiple system atrophy, which is a rare, progressive, fatal neurological disorder. In a mouse model of multiple system atrophy, rifampicin inhibited formation of α-synuclein fibrils, the neuropathological hallmark of the disease. We aimed to assess the safety and efficacy of rifampicin in patients with multiple system atrophy. METHODS In this randomised, double-blind, placebo-controlled trial we recruited participants aged 30-80… CONTINUE READING
Related Discussions
This paper has been referenced on Twitter 8 times. VIEW TWEETS

Citations

Publications citing this paper.
Showing 1-10 of 26 extracted citations

The Oligomer Hypothesis in α-Synucleinopathy

Neurochemical Research • 2017
View 8 Excerpts
Highly Influenced

Alpha-synuclein biology in Lewy body diseases

Alzheimer's Research & Therapy • 2014
View 11 Excerpts
Highly Influenced

First symptoms in multiple system atrophy

Clinical Autonomic Research • 2017
View 1 Excerpt

Similar Papers

Loading similar papers…